Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'

Jefferies Upgrades Merck (MRK) to Hold

October 31, 2017 3:51 AM EDT

Jefferies upgraded Merck (NYSE: MRK) from Underperform to Hold with a price target of $55.00 (from $54.00).

Analyst Jeffery Holford believes the sharp move lower recently has removed much of the downside he previously suspected would manifest and now moves to the... More

Merck (MRK) Defended at BMO Capital

October 30, 2017 1:13 PM EDT

BMO Capital analyst Alex Arfaei came out to defend Merck (NYSE: MRK) which is down 5.9% after the company announced that it has withdrawn its European application for KEYTRUDA® (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell... More

Merck (MRK) PT Lowered to $64 at Bernstein

October 30, 2017 8:09 AM EDT

Bernstein lowered its price target on Merck (NYSE: MRK) to $64.00 (from $65.00) while maintaining a Outperform rating.

Analyst Tim Anderson defends the name noting he continues to view the IO landscape as a "fluid one" and notes risks to IO forecasts are... More

Merck (MRK) PT Lowered to $69 at Leerink Partners

October 30, 2017 7:49 AM EDT

Leerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results

Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.

... More

Wall Street slips as Merck drops, tax talk rattles

October 30, 2017 7:21 AM EDT

By Lewis Krauskopf

(Reuters) - Wall Street pulled back from record-high territory on Monday, weighed down by a drop in Merck shares and a report that U.S. lawmakers are discussing a gradual phase-in of much-anticipated corporate tax cuts.

Market watchers pointed to declines steepening after a Bloomberg report that the House of Representatives was discussing a gradual cut in corporate tax rates over several years.

"A lot of people are looking to that corporate tax cut as a reason for the next leg up in stocks," said Rick Meckler, president of LibertyView Capital Management in Jersey City,... More

SunTrust Robinson Humphrey Downgrades Merck (MRK) to Hold

October 30, 2017 5:26 AM EDT

SunTrust Robinson Humphrey downgraded Merck (NYSE: MRK) from Buy to Hold with a price target of $54.00 (from $73.00).

Analyst John Boris adjusts his model to account for Keytruda application withdraw and rising competition for Merck.

For an analyst ratings summary and... More

Morgan Stanley Downgrades Merck (MRK) to Equalweight

October 30, 2017 2:11 AM EDT

Morgan Stanley downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $56.00 (from $69.00).

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $58.24 Friday.

... More

Barclays Downgrades Merck (MRK) to Equalweight

October 30, 2017 2:05 AM EDT

Barclays downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $62.00 (from $72.00).

Analyst Geoff Meacham cites limited upside potential for the equity originating from Keytruda which is "by far Meerck's biggest value driver." The analyst notes headwinds to the... More

Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC

October 27, 2017 4:18 PM EDT

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its European application for KEYTRUDA® (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).

... More

Wall St. powered higher by tech, Amazon results

October 27, 2017 7:38 AM EDT

By Chuck Mikolajczak

NEW YORK (Reuters) - Wall Street climbed on Friday as a surge in the tech sector and a rally in Amazon shares helped push the Nasdaq to its best day in nearly a year.

The S&P technology index led the way higher, up 2.91 percent. The index notched its best day since March 1, 2016, and is up nearly 35 percent on the year versus the 15 percent gain in the S&P 500.

Google-parent Alphabet (NASDAQ: GOOGL) gained 4.26 percent as its revenue got a boost from advertising sales.

Microsoft (NASDAQ:... More

Merck (MRK) Tops Q3 EPS by 8c, Lifts FY EPS Gudiance

October 27, 2017 6:46 AM EDT

(Updated - October 27, 2017 6:49 AM EDT)

Merck (NYSE: MRK) reported Q3 EPS of $1.11, $0.08 better than the analyst estimate of $1.03. Revenue for the quarter came in at $10.3 billion versus the consensus estimate of $10.55 billion.

Financial... More